BRPI0813176A2 - Moléculas e composições par ainibir fator edema e adenilil ciclase - Google Patents

Moléculas e composições par ainibir fator edema e adenilil ciclase

Info

Publication number
BRPI0813176A2
BRPI0813176A2 BRPI0813176-7A2A BRPI0813176A BRPI0813176A2 BR PI0813176 A2 BRPI0813176 A2 BR PI0813176A2 BR PI0813176 A BRPI0813176 A BR PI0813176A BR PI0813176 A2 BRPI0813176 A2 BR PI0813176A2
Authority
BR
Brazil
Prior art keywords
adenylil
cyclase
molecules
compositions
factor
Prior art date
Application number
BRPI0813176-7A2A
Other languages
English (en)
Inventor
Catherine H Schein
Deliang Chen
Scott R Gilbertson
Maria Estrella-Jimmenez
Jian Gao
Mary A Walter
Johnny W Peterson
Original Assignee
Mission Pharma Co
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40468705&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0813176(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mission Pharma Co, Univ Texas filed Critical Mission Pharma Co
Publication of BRPI0813176A2 publication Critical patent/BRPI0813176A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0813176-7A2A 2007-06-15 2008-06-13 Moléculas e composições par ainibir fator edema e adenilil ciclase BRPI0813176A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94437507P 2007-06-15 2007-06-15
US3526908P 2008-03-10 2008-03-10
PCT/US2008/066898 WO2009038842A2 (en) 2007-06-15 2008-06-13 Methods and compositions to inhibit edema factor and adenylyl cyclase

Publications (1)

Publication Number Publication Date
BRPI0813176A2 true BRPI0813176A2 (pt) 2014-12-30

Family

ID=40468705

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0813176-7A2A BRPI0813176A2 (pt) 2007-06-15 2008-06-13 Moléculas e composições par ainibir fator edema e adenilil ciclase

Country Status (12)

Country Link
US (2) US8003692B2 (pt)
EP (1) EP2166841A4 (pt)
CN (1) CN101784274A (pt)
AR (1) AR067850A1 (pt)
AU (1) AU2008302667B2 (pt)
BR (1) BRPI0813176A2 (pt)
CA (1) CA2692004C (pt)
CL (1) CL2008001782A1 (pt)
CO (1) CO6270184A2 (pt)
DO (1) DOP2009000272A (pt)
MX (1) MX2009013676A (pt)
WO (1) WO2009038842A2 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101636157A (zh) * 2007-01-12 2010-01-27 康乃尔研究基金会有限公司 作为抗菌干预的新型靶的腺苷酰环化酶
US9095578B2 (en) * 2007-01-12 2015-08-04 Cornell Research Foundation, Inc. Adenylyl cyclases as novel targets for the treatment of infection by eukaryotic pathogens
CA2692004C (en) * 2007-06-15 2013-04-09 Board Of Regents, The University Of Texas System Methods and compositions to inhibit edema factor and adenylyl cyclase
US8183007B2 (en) * 2008-07-22 2012-05-22 Promega Corporation ADP detection based methods using adenylate cyclase and bioluminescence
BRPI1013392A2 (pt) * 2009-03-31 2016-03-29 Renascience Co Ltd inibidor do inibidor-1 do ativador do plasminogênio
JP2015506360A (ja) * 2012-01-06 2015-03-02 ユニバーシティ・オブ・サウス・フロリダ 組成物、使用方法および処置方法
WO2014171464A1 (ja) 2013-04-15 2014-10-23 株式会社レナサイエンス Ｐａｉ－１阻害剤の新規用途
WO2016057084A1 (en) 2014-10-08 2016-04-14 Promega Corporation Bioluminescent succinate detection assay
CN105218343B (zh) * 2015-10-26 2017-03-22 乐普药业股份有限公司 一种3‑溴环己‑2‑烯‑1‑酮的合成方法
JP2020505439A (ja) * 2017-01-10 2020-02-20 オーウェン−バリー・ファーマシューティカルズ・インコーポレイテッドＯｗｅｎ−Ｂａｒｒｙ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 抗痙攣薬化合物
RU2764243C2 (ru) 2017-09-22 2022-01-14 ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи Гетероциклические соединения в качестве ингибиторов PAD
US10882821B1 (en) 2017-09-26 2021-01-05 The Board Of Trustees Of The Leland Stanford Junior University Enantiomeric compound for the reduction of the deleterious activity of extended nucleotide repeat containing genes
CN111225915B (zh) 2017-10-18 2023-03-07 朱比兰特埃皮帕德有限公司 作为pad抑制剂的咪唑并吡啶化合物
US11629135B2 (en) 2017-11-06 2023-04-18 Jubilant Prodell Llc Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
RS65576B1 (sr) 2017-11-24 2024-06-28 Jubilant Episcribe Llc Heterociklična jedinjenja kao inhibitori prmt5
CN112105610B (zh) 2018-03-13 2024-01-26 朱比连特普罗德尔有限责任公司 作为pd1/pd-l1相互作用/活化的抑制剂的双环化合物
TWI904890B (zh) * 2024-10-14 2025-11-11 明志科技大學 鋅金屬有機框架材料及其用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4066834A (en) * 1974-01-24 1978-01-03 Miles Laboratories, Inc. Cycloalkenyl analogues of prostaglandins E
US4222944A (en) * 1978-07-31 1980-09-16 Hoffmann-La Roche Inc. Halo-3-dibenzofuran alkanonitriles
KR20000068415A (ko) * 1996-09-04 2000-11-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 매트릭스 메탈로프로테이나제 억제용 화합물 및 방법
EP1165092A1 (en) 1999-03-22 2002-01-02 Charterhouse Therapeutics Ltd. Cyclopentanone derivatives and their use
EP1353664A2 (en) * 2000-06-08 2003-10-22 The Board Of Regents, The University Of Texas System Heterocycle derivatives and methods of use for treating anthrax infection
AU2002239277A1 (en) * 2000-11-20 2002-05-27 Cor Therapeutics, Inc. Adenine based inhibitors of adenylyl cyclase, pharmaceutical compositions and method of use thereof
AU2002217316A1 (en) * 2001-01-03 2002-07-30 Medpharma Plc Use of terpenes for the treatment of digestive tract infections
DE10123163A1 (de) * 2001-05-09 2003-01-16 Gruenenthal Gmbh Substituierte Cyclohexan-1,4-diaminderivate
MXPA04001253A (es) * 2001-08-09 2004-06-03 Ono Pharmaceutical Co Derivados de acidos carboxilicos y agente farmaceutico que comprende los mismos como ingrediente activo.
JP2005511791A (ja) * 2001-12-14 2005-04-28 チャーターハウス セラピューティックス リミテッド 医薬組成物の改良
US20030157159A1 (en) * 2002-01-15 2003-08-21 Franklin Lanny Udell Prevention and treatment of digestive tract infections
US20030224403A1 (en) * 2002-02-27 2003-12-04 Popov Serguei G. Lethal toxin cytopathogenicity and novel approaches to anthrax treatment
ZA200502496B (en) * 2002-02-28 2005-10-12 Japan Tobacco Inc Ester compound and medicinal use thereof.
KR20050065624A (ko) * 2002-10-23 2005-06-29 그렌마크 파머수티칼스 엘티디. 염증성 및 알레르기 질환의 치료에 유용한 신규한트리사이클릭 화합물, 이의 제조 방법 및 이를 함유하는약제 조성물
JP2007516203A (ja) * 2003-07-09 2007-06-21 バイオリポックス エービー 炎症の治療に有用なインドール類
US7223759B2 (en) * 2003-09-15 2007-05-29 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds
CA2881078C (en) * 2004-06-24 2018-10-02 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US20080096848A1 (en) * 2004-09-29 2008-04-24 Cytovia Inc. Substituted N-Aryl-9-Oxo-9H-Fluorene-1-Carboxamides and Analogs as Activators of Caspases and Inducers of Apoptosis
US7091231B2 (en) * 2004-12-10 2006-08-15 Allergan, Inc. 12-Aryl prostaglandin analogs
WO2007076055A2 (en) * 2005-12-22 2007-07-05 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
JP2009537598A (ja) * 2006-05-23 2009-10-29 ノイロサーチ アクティーゼルスカブ 新規１，４−ジアザ−ビシクロ［３．２．２］ノナン誘導体及びそれらの医学的使用
CA2692004C (en) * 2007-06-15 2013-04-09 Board Of Regents, The University Of Texas System Methods and compositions to inhibit edema factor and adenylyl cyclase

Also Published As

Publication number Publication date
AR067850A1 (es) 2009-10-28
CA2692004C (en) 2013-04-09
WO2009038842A3 (en) 2009-12-30
DOP2009000272A (es) 2010-02-15
US20120010233A1 (en) 2012-01-12
MX2009013676A (es) 2010-06-01
EP2166841A4 (en) 2014-05-07
AU2008302667B2 (en) 2014-07-10
CO6270184A2 (es) 2011-04-20
US20090093519A1 (en) 2009-04-09
WO2009038842A2 (en) 2009-03-26
EP2166841A2 (en) 2010-03-31
CA2692004A1 (en) 2009-03-26
CL2008001782A1 (es) 2008-11-03
US8003692B2 (en) 2011-08-23
CN101784274A (zh) 2010-07-21
AU2008302667A1 (en) 2009-03-26

Similar Documents

Publication Publication Date Title
LTPA2018014I1 (lt) Farmacinė kompozicija 514
PL2214679T3 (pl) Kompozycje kortykosteroidów
SMT201500176B (it) Composizioni e metodi per inibire l'espressione ditranstiretina
EP2200550A4 (en) TOPICAL GLYCOPYRROLATE FORMULATIONS
BRPI0913806A2 (pt) "composição"
ME01423B (me) Fungicidni sastavi
HUE059171T2 (hu) Kompozíciók
DK2185157T3 (da) Dhea-sammensætninger til at behandle menopause
EP2280916A4 (en) HYDROCHLORFLUOROLEFINZUSAMMENSETZUNGEN
BRPI0815407A2 (pt) Composições e métodos para controlar nematódeos
BRPI0817473A2 (pt) plataforma de aplicativo para executar aplicativos
BRPI0909174A2 (pt) Composição cosméticas para proporcionar peliculas super hidrofóbicas
EP2110390A4 (en) POLYMERIZABLE COMPOSITION
BRPI0813775A2 (pt) Composição
BRPI0818007A2 (pt) composição para regular o metabolismo lipídico
BRPI0913945A2 (pt) agentes anti-inflamatórios
EP2037872A4 (en) COMPOSITIONS WITH BETULONIC ACID
ATE528048T1 (de) Schweisshemmende/desodorierende zusammensetzung
LT2966175T (lt) Farmacinės kompozicijos turinčios korteksolono-17-alfa-propionato
BRPI0814165A2 (pt) Composições tópicas endoparasiticidas
BRPI0810557A2 (pt) composição
PL2301525T3 (pl) Preparat ibuprofenu do stosowania miejscowego
BRPI0811274A2 (pt) Composição
DK2280706T3 (da) Lipasa-aktiverende lipoproteinsammensætninger omfattende benzenderivater
EP2318306A4 (en) NANO COMPOSITIONS

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]